AVA NewTechnology

AVA NewTechnology

At AVA NewTechnology, we are laying the foundation for groundbreaking precision medical diagnostic-, and therapy technologies with a focus on hemato-oncological diseases.
The first big success of AVA NewTechnology is the development of our proprietary AVA-NextGenMonoclonalsTM platform. It allows the identification of unique monoclonal antibodies (AVA-mAbsTM) of the highest specificity for use in precision medicine.
With the AVA-NextGenMonoclonalsTM platform, we are focusing on precision medical approaches, acting as spearhead in the establishment of efficient haemato-oncological companion diagnostics (CDx).

 

Image

Activities of AVA LifeScience

Currently, we concentrate on B-cell-associated diseases with a focus on aggressive forms of CLL. We have expanded our scope with projects dealing with other B cell-associated diseases (e.g. diffuse large cell B-cell lymphoma).

Our explicit goal for the future is the development of specific mABs against autoimmune diseases, e.g. Multiple Sclerosis or Rheumatoid Arthritis.

AVA-NextGenMonoclonals™

Exceptional possibilities through unsurpassed precision.

The first product of the AVA-NextGenMonoclonalsTM platform is AVA-mAb01TM, which opens up a completely new world for targeted therapies with its exceptional tumor specificity.
AVA-mAb01TM is directed against a specific surface structure present on malignant B-cells of an aggressive chronic lymphocytic leukemia (CLL) form. Due to its high accuracy, AVA-mAb01TM allows not only stratified pharmacotherapy but also the establishment of an innovative companion diagnostics.